This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lagace, D. C. Articles by Nachtigal, M. W. Search for Related Content PubMed PubMed Citation Articles by Lagace, D. C. Articles by Nachtigal, M. W.

Valproic Acid Inhibits Leptin Secretion and Reduces Leptin Messenger Ribonucleic Acid Levels in Adipocytes

Departments of Pharmacology (D.C.L., M.W.N.) and Biochemistry and Molecular Biology (R.S.M.), Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada B3H 1X5

Address all correspondence and requests for reprints to: M. W. Nachtigal, Department of Pharmacology, 5850 College Street, Dalhousie University, Halifax, Nova Scotia, Canada B3H 1X5. E-mail: mark.nachtigal{at}dal.ca.

Treatment of epilepsy or bipolar disorder with valproic acid (VPA) induces weight gain and increased serum levels for the satiety hormone, leptin, through an unidentified mechanism. In this study we tested the effects of VPA, a short-chain branched fatty acid (C8:0), on leptin biology and fatty acid metabolism in 3T3-L1 adipocytes. VPA significantly reduced leptin secretion in a dose-dependent manner. Because fatty acid accumulation has been hypothesized to block leptin secretion, we tested the effect of VPA on fatty acid metabolism. Using ¹⁴C-radiolabeled VPA, we found that the ¹⁴C was mainly incorporated into triacylglycerol. VPA did not alter lipogenesis from acetate, nor did it change the amount of intracellular free fatty acids available for triacylglycerol synthesis. Decreased leptin secretion was accompanied by a reduction in leptin mRNA, even though VPA treatment did not alter the protein levels for known transcription factors affecting leptin transcription including: CCAAT/enhancer binding protein-, peroxisome proliferator-activated receptor-, or steroid regulatory element binding protein 1a. VPA altered levels of leptin mRNA independent of de novo protein synthesis without affecting leptin mRNA degradation. This report demonstrates that VPA decreases leptin secretion and mRNA levels in adipocytes in vitro, suggesting that VPA therapy may be associated with altered leptin homeostasis contributing to weight gain in vivo.

This article has been cited by other articles:

				K. B. Goralski, T. C. McCarthy, E. A. Hanniman, B. A. Zabel, E. C. Butcher, S. D. Parlee, S. Muruganandan, and C. J. Sinal Chemerin, a Novel Adipokine That Regulates Adipogenesis and Adipocyte Metabolism J. Biol. Chem., September 21, 2007; 282(38): 28175 - 28188. [Abstract] [Full Text] [PDF]

				L. Qiao, J. Schaack, and J. Shao Suppression of Adiponectin Gene Expression by Histone Deacetylase Inhibitor Valproic Acid Endocrinology, February 1, 2006; 147(2): 865 - 874. [Abstract] [Full Text] [PDF]

				R. Morriss and F. A. Mohammed Metabolism, lifestyle and bipolar affective disorder J Psychopharmacol, November 1, 2005; 19(6_suppl): 94 - 101. [Abstract] [PDF]